Mirati therapeutics, inc. (MRTX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities:
Net loss

-213,256

-98,418

-70,430

-83,118

-64,544

-43,698

-52,859

-20,286

Non-cash adjustments reconciling net loss to operating cash flows:
Depreciation

200

175

184

180

212

199

171

123

Accretion of discount on investments

3,421

1,320

266

-7

-337

534

0

0

Share-based compensation expense

55,537

15,854

6,786

10,624

10,254

7,050

1,823

2,009

Loss on disposal of property and equipment

-

-

-

-

-

-

-40

0

Change in lease incentive liability

-

-

-

-

-

-

-70

85

Change in fair value of warrant liability

-

-

-

-

-

4,517

19,799

0

Change in fair value adjustment of share-based compensation liability

-

-

-

-

-

-

1,369

0

Change in restructuring costs

-

-

-

-

-

-

0

0

Changes in operating assets and liabilities:
Other current assets

5,487

-1,052

3,409

-254

-279

1,209

-340

15

Other long-term assets

4,375

359

-3,606

1,259

1,675

326

0

0

Accounts payable, accrued liabilities, deferred revenue and other liabilities

23,027

12,920

-1,177

5,295

4,370

151

-68

1,434

Other current and long term liabilities

-

-

-

-

53

21

0

0

Cash flows used in operating activities

-147,726

-70,096

-64,706

-68,017

-50,714

-32,748

-29,455

-16,650

Investing activities:
Purchases of short-term investments

530,228

255,795

100,558

70,269

104,954

10,468

68,408

29,431

Sales and maturities of short-term investments

355,640

110,152

91,988

108,720

54,530

35,073

39,138

29,716

Purchases of property, plant, and equipment

1,552

122

81

196

329

386

204

230

Proceeds from disposal of property and equipment

-

-

-

-

-

-

4

0

Cash flows used in investing activities

-176,140

-145,765

-8,651

38,255

-50,753

24,219

-29,470

55

Financing activities:
Proceeds from issuance of common stock, net of issuance costs

327,830

130,663

153,530

0

143,293

0

54,196

19,886

Proceeds from issuances under employee stock purchase plan

675

442

144

297

522

0

0

4,927

Proceeds from exercise of common stock options and warrants

8,473

9,747

5,003

2,355

552

887

561

0

Proceeds from disgorgement of shareholders' short-swing profits

1,050

0

0

-

-

-

-

-

Cash flows provided by financing activities

338,028

140,852

158,677

2,652

144,367

887

54,757

24,813

Increase in cash, cash equivalents and restricted cash

14,162

-75,009

85,320

-27,110

42,900

-7,642

-4,168

8,218

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

303

Supplemental disclosures of non-cash investing activities:
Income taxes paid

-

-

-

-

-

-

35

34

Net exercise of warrants

-

-

-

-

0

993

2,586

0